<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875277</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ-003</org_study_id>
    <nct_id>NCT00875277</nct_id>
  </id_info>
  <brief_title>A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products</brief_title>
  <official_title>A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to DaivobetÂ® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its
      combination with calcipotriol and betamethasone using a psoriasis plaque test method.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)</measure>
    <time_frame>From baseline (Day 1) to end of treatment (Day 29)</time_frame>
    <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline</measure>
    <time_frame>From baseline (Day 1) to end of treatment (Day 29)</time_frame>
    <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythema Compared to Baseline</measure>
    <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22 and Day 25</time_frame>
    <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scaling Compared to Baseline</measure>
    <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25</time_frame>
    <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Infiltration Compared to Baseline</measure>
    <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25</time_frame>
    <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline</measure>
    <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25</time_frame>
    <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound</measure>
    <time_frame>At Day 8, Day 15, Day 22 and end of treatment</time_frame>
    <description>The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers by Immunochemistry</measure>
    <time_frame>At end of treatment</time_frame>
    <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
Cells counted per mm^2 were cells that were positive for the indicated biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers by Immunochemistry: Epidermal Differentiation</measure>
    <time_frame>At end of treatment</time_frame>
    <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers by Immunochemistry: Epidermal Proliferation</measure>
    <time_frame>At end of treatment</time_frame>
    <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm^2 were cells that were positive for the indicated biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathology and Histology by Treatment</measure>
    <time_frame>At end of treatment</time_frame>
    <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below:
Morphology of epidermis
Stratum corneum (semi (extent of))
Stratum granulosum (semi (extent of))
Parakeratosis (semi (extent of))
Infiltration of inflammatory cells (semi (extent of))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathology and Histology by Treatment: Epidermal Thickness</measure>
    <time_frame>At end of treatment</time_frame>
    <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of Âµm measured on blinded haematoxylin and eosin (HE) sections..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses</measure>
    <time_frame>At end of treatment</time_frame>
    <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study.
In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (MonroeÂ´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 29102 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 Cream Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone Dipropionate Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 Plus Calcipotriol Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 Plus Betamethasone Dipropionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DaivobetÂ® Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 cream</intervention_name>
    <arm_group_label>LEO 29102 cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 Cream Vehicle</intervention_name>
    <arm_group_label>LEO 29102 Cream Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone Dipropionate Cream</intervention_name>
    <arm_group_label>Betamethasone Dipropionate Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 Plus Calcipotriol Cream</intervention_name>
    <arm_group_label>LEO 29102 Plus Calcipotriol Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 Plus Betamethasone Dipropionate</intervention_name>
    <arm_group_label>LEO 29102 Plus Betamethasone Dipropionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaivobetÂ® Ointment</intervention_name>
    <arm_group_label>DaivobetÂ® Ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (in summary)

          -  Subjects having understood and signed an informed consent form

          -  All skin types

          -  Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or
             trunk. The lesions must have a total size suitable for application. The subjects
             should be asked if their lesions have been stable

          -  Subjects willing and able to follow all the study procedures and complete the whole
             study

          -  Subjects affiliated to social security system

        Exclusion Criteria: (in summary)

          -  Females who are pregnant, of child-bearing potential and who wish to become pregnant
             during the study, or who are breast feeding

          -  Subjects using biological therapies (marketed or not marketed) with a possible effect
             on psoriasis (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab) within
             12 weeks prior to study drug administration

          -  Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D-analogues, retinoids,
             immunosuppressants) within the 4-week period prior to randomisation

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within four (4) weeks prior to study drug administration: - Potent or very potent (WHO
             group III-IV) corticosteroids - PUVA or Grenz ray therapy

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within two (2) weeks prior to study drug administration: - WHO group I-II
             corticosteroids - Topical retinoids - Vitamin D-analogues - Topical immunomodulators
             (e.g. macrolides) - Anthracen derivatives - Tar - Salicylic acid - UVB therapy

          -  Subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea,
             perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of
             skin veins, ichthyosis, acne rosacea, ulcers and wounds within the plaque test areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, International Clinical Development, MD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma site</name>
      <address>
        <city>Saint-Quentin-en-Yvelines</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <results_first_submitted>August 20, 2018</results_first_submitted>
  <results_first_submitted_qc>December 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2019</results_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were treated with the investigational medicinal products for 4 weeks followed by a 10-day follow-up period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Randomized Participants</title>
          <description>All randomized participants received the six investigational medicinal products on six different test sites. LEO 29102 cream, LEO 29102 plus calcipotriol cream, LEO 29102 plus betamethasone dipropionate cream, DaivobetÂ® ointment, Betamethasone dipropionate cream, and LEO 29102 cream vehicle applied topically once daily six times a week for 4 weeks (not on Sundays) on six different 2-cm diameter site (one per study preparation).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Participants</title>
          <description>All randomized participants received the six products on six different test sites.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)</title>
        <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
        <time_frame>From baseline (Day 1) to end of treatment (Day 29)</time_frame>
        <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)</title>
          <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
          <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="1.18"/>
                    <measurement group_id="O2" value="-4.96" spread="1.99"/>
                    <measurement group_id="O3" value="-3.04" spread="1.34"/>
                    <measurement group_id="O4" value="-3.96" spread="1.49"/>
                    <measurement group_id="O5" value="-5.56" spread="1.28"/>
                    <measurement group_id="O6" value="-6.10" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline</title>
        <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
        <time_frame>From baseline (Day 1) to end of treatment (Day 29)</time_frame>
        <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline</title>
          <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
          <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.48"/>
                    <measurement group_id="O2" value="-1.71" spread="0.81"/>
                    <measurement group_id="O3" value="-0.90" spread="0.55"/>
                    <measurement group_id="O4" value="-1.19" spread="0.70"/>
                    <measurement group_id="O5" value="-1.85" spread="0.63"/>
                    <measurement group_id="O6" value="-1.88" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.33"/>
                    <measurement group_id="O2" value="-1.46" spread="0.75"/>
                    <measurement group_id="O3" value="-0.85" spread="0.52"/>
                    <measurement group_id="O4" value="-1.17" spread="0.50"/>
                    <measurement group_id="O5" value="-1.75" spread="0.53"/>
                    <measurement group_id="O6" value="-2.04" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaliness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.57"/>
                    <measurement group_id="O2" value="-1.79" spread="0.62"/>
                    <measurement group_id="O3" value="-1.29" spread="0.51"/>
                    <measurement group_id="O4" value="-1.60" spread="0.55"/>
                    <measurement group_id="O5" value="-1.96" spread="0.41"/>
                    <measurement group_id="O6" value="-2.19" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Erythema Compared to Baseline</title>
        <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red</description>
        <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22 and Day 25</time_frame>
        <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erythema Compared to Baseline</title>
          <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red</description>
          <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 5 (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.25"/>
                    <measurement group_id="O2" value="-0.21" spread="0.29"/>
                    <measurement group_id="O3" value="-0.02" spread="0.18"/>
                    <measurement group_id="O4" value="-0.08" spread="0.24"/>
                    <measurement group_id="O5" value="-0.40" spread="0.42"/>
                    <measurement group_id="O6" value="-0.38" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.38"/>
                    <measurement group_id="O2" value="-0.67" spread="0.46"/>
                    <measurement group_id="O3" value="-0.31" spread="0.32"/>
                    <measurement group_id="O4" value="-0.29" spread="0.29"/>
                    <measurement group_id="O5" value="-0.92" spread="0.43"/>
                    <measurement group_id="O6" value="-0.88" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.33"/>
                    <measurement group_id="O2" value="-0.94" spread="0.47"/>
                    <measurement group_id="O3" value="-0.46" spread="0.33"/>
                    <measurement group_id="O4" value="-0.44" spread="0.37"/>
                    <measurement group_id="O5" value="-1.17" spread="0.43"/>
                    <measurement group_id="O6" value="-1.19" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.36"/>
                    <measurement group_id="O2" value="-1.23" spread="0.69"/>
                    <measurement group_id="O3" value="-0.60" spread="0.36"/>
                    <measurement group_id="O4" value="-0.77" spread="0.42"/>
                    <measurement group_id="O5" value="-1.46" spread="0.59"/>
                    <measurement group_id="O6" value="-1.40" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 17 (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.40"/>
                    <measurement group_id="O2" value="-1.33" spread="0.76"/>
                    <measurement group_id="O3" value="-0.75" spread="0.42"/>
                    <measurement group_id="O4" value="-0.98" spread="0.40"/>
                    <measurement group_id="O5" value="-1.71" spread="0.61"/>
                    <measurement group_id="O6" value="-1.63" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.49"/>
                    <measurement group_id="O2" value="-1.48" spread="0.80"/>
                    <measurement group_id="O3" value="-0.83" spread="0.55"/>
                    <measurement group_id="O4" value="-1.04" spread="0.51"/>
                    <measurement group_id="O5" value="-1.75" spread="0.66"/>
                    <measurement group_id="O6" value="-1.85" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 23 (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.43"/>
                    <measurement group_id="O2" value="-1.54" spread="0.81"/>
                    <measurement group_id="O3" value="-0.85" spread="0.54"/>
                    <measurement group_id="O4" value="-1.08" spread="0.50"/>
                    <measurement group_id="O5" value="-1.83" spread="0.72"/>
                    <measurement group_id="O6" value="-1.94" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Scaling Compared to Baseline</title>
        <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales</description>
        <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25</time_frame>
        <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50 mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Scaling Compared to Baseline</title>
          <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales</description>
          <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 5 (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.35"/>
                    <measurement group_id="O2" value="-0.31" spread="0.41"/>
                    <measurement group_id="O3" value="-0.13" spread="0.30"/>
                    <measurement group_id="O4" value="-0.21" spread="0.41"/>
                    <measurement group_id="O5" value="-0.33" spread="0.43"/>
                    <measurement group_id="O6" value="-0.52" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.42"/>
                    <measurement group_id="O2" value="-0.88" spread="0.61"/>
                    <measurement group_id="O3" value="-0.44" spread="0.58"/>
                    <measurement group_id="O4" value="-0.63" spread="0.58"/>
                    <measurement group_id="O5" value="-1.17" spread="0.67"/>
                    <measurement group_id="O6" value="-1.19" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.33"/>
                    <measurement group_id="O2" value="-1.15" spread="0.54"/>
                    <measurement group_id="O3" value="-0.63" spread="0.42"/>
                    <measurement group_id="O4" value="-0.71" spread="0.61"/>
                    <measurement group_id="O5" value="-1.48" spread="0.58"/>
                    <measurement group_id="O6" value="-1.92" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.52"/>
                    <measurement group_id="O2" value="-1.33" spread="0.64"/>
                    <measurement group_id="O3" value="-0.73" spread="0.47"/>
                    <measurement group_id="O4" value="-1.00" spread="0.55"/>
                    <measurement group_id="O5" value="-1.67" spread="0.58"/>
                    <measurement group_id="O6" value="-2.04" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 17 (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.45"/>
                    <measurement group_id="O2" value="-1.56" spread="0.60"/>
                    <measurement group_id="O3" value="-0.90" spread="0.47"/>
                    <measurement group_id="O4" value="-1.15" spread="0.54"/>
                    <measurement group_id="O5" value="-1.83" spread="0.58"/>
                    <measurement group_id="O6" value="-2.13" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.29"/>
                    <measurement group_id="O2" value="-1.54" spread="0.62"/>
                    <measurement group_id="O3" value="-0.81" spread="0.44"/>
                    <measurement group_id="O4" value="-1.27" spread="0.42"/>
                    <measurement group_id="O5" value="-1.75" spread="0.53"/>
                    <measurement group_id="O6" value="-2.19" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 23 (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.42"/>
                    <measurement group_id="O2" value="-1.81" spread="0.60"/>
                    <measurement group_id="O3" value="-1.17" spread="0.55"/>
                    <measurement group_id="O4" value="-1.46" spread="0.57"/>
                    <measurement group_id="O5" value="-2.00" spread="0.42"/>
                    <measurement group_id="O6" value="-2.21" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Infiltration Compared to Baseline</title>
        <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration</description>
        <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25</time_frame>
        <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50 mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Infiltration Compared to Baseline</title>
          <description>The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale.
The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration</description>
          <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 5 (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.27"/>
                    <measurement group_id="O2" value="-0.10" spread="0.29"/>
                    <measurement group_id="O3" value="-0.04" spread="0.20"/>
                    <measurement group_id="O4" value="0.00" spread="0.21"/>
                    <measurement group_id="O5" value="-0.27" spread="0.25"/>
                    <measurement group_id="O6" value="-0.29" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.31"/>
                    <measurement group_id="O2" value="-0.38" spread="0.34"/>
                    <measurement group_id="O3" value="-0.13" spread="0.34"/>
                    <measurement group_id="O4" value="-0.29" spread="0.51"/>
                    <measurement group_id="O5" value="-0.73" spread="0.47"/>
                    <measurement group_id="O6" value="-0.79" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.37"/>
                    <measurement group_id="O2" value="-0.77" spread="0.51"/>
                    <measurement group_id="O3" value="-0.31" spread="0.38"/>
                    <measurement group_id="O4" value="-0.46" spread="0.39"/>
                    <measurement group_id="O5" value="-1.06" spread="0.50"/>
                    <measurement group_id="O6" value="-1.29" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.33"/>
                    <measurement group_id="O2" value="-0.98" spread="0.60"/>
                    <measurement group_id="O3" value="-0.42" spread="0.43"/>
                    <measurement group_id="O4" value="-0.69" spread="0.38"/>
                    <measurement group_id="O5" value="-1.35" spread="0.65"/>
                    <measurement group_id="O6" value="-1.79" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 17 (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.35"/>
                    <measurement group_id="O2" value="-1.10" spread="0.61"/>
                    <measurement group_id="O3" value="-0.58" spread="0.46"/>
                    <measurement group_id="O4" value="-0.75" spread="0.39"/>
                    <measurement group_id="O5" value="-1.50" spread="0.63"/>
                    <measurement group_id="O6" value="-1.94" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.29"/>
                    <measurement group_id="O2" value="-1.25" spread="0.66"/>
                    <measurement group_id="O3" value="-0.56" spread="0.47"/>
                    <measurement group_id="O4" value="-0.90" spread="0.33"/>
                    <measurement group_id="O5" value="-1.67" spread="0.62"/>
                    <measurement group_id="O6" value="-1.98" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 23 (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.34"/>
                    <measurement group_id="O2" value="-1.35" spread="0.73"/>
                    <measurement group_id="O3" value="-0.73" spread="0.47"/>
                    <measurement group_id="O4" value="-1.06" spread="0.40"/>
                    <measurement group_id="O5" value="-1.67" spread="0.60"/>
                    <measurement group_id="O6" value="-2.02" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline</title>
        <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
        <time_frame>At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline</title>
          <description>The (sub)investigator made the following clinical assessments by use of the scale below:
Score; Intensity; Description
Erythema:
0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Scaling:
0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Infiltration:
0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 5 (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.66"/>
                    <measurement group_id="O2" value="-0.63" spread="0.80"/>
                    <measurement group_id="O3" value="-0.19" spread="0.53"/>
                    <measurement group_id="O4" value="-0.29" spread="0.66"/>
                    <measurement group_id="O5" value="-1.00" spread="0.88"/>
                    <measurement group_id="O6" value="-1.19" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.78"/>
                    <measurement group_id="O2" value="-1.92" spread="1.18"/>
                    <measurement group_id="O3" value="-0.88" spread="0.97"/>
                    <measurement group_id="O4" value="-1.21" spread="1.07"/>
                    <measurement group_id="O5" value="-2.81" spread="1.26"/>
                    <measurement group_id="O6" value="-2.85" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.75"/>
                    <measurement group_id="O2" value="-2.85" spread="1.26"/>
                    <measurement group_id="O3" value="-1.40" spread="0.90"/>
                    <measurement group_id="O4" value="-1.60" spread="1.11"/>
                    <measurement group_id="O5" value="-3.71" spread="1.28"/>
                    <measurement group_id="O6" value="-4.40" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.89"/>
                    <measurement group_id="O2" value="-3.54" spread="1.66"/>
                    <measurement group_id="O3" value="-1.75" spread="1.12"/>
                    <measurement group_id="O4" value="-2.46" spread="1.00"/>
                    <measurement group_id="O5" value="-4.48" spread="1.56"/>
                    <measurement group_id="O6" value="-5.23" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 17 (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="0.95"/>
                    <measurement group_id="O2" value="-4.00" spread="1.72"/>
                    <measurement group_id="O3" value="-2.23" spread="1.11"/>
                    <measurement group_id="O4" value="-2.88" spread="0.99"/>
                    <measurement group_id="O5" value="-5.04" spread="1.46"/>
                    <measurement group_id="O6" value="-5.69" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.83"/>
                    <measurement group_id="O2" value="-4.27" spread="1.92"/>
                    <measurement group_id="O3" value="-2.21" spread="1.20"/>
                    <measurement group_id="O4" value="-3.21" spread="0.98"/>
                    <measurement group_id="O5" value="-5.17" spread="1.64"/>
                    <measurement group_id="O6" value="-6.02" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 23 (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="0.97"/>
                    <measurement group_id="O2" value="-4.71" spread="1.99"/>
                    <measurement group_id="O3" value="-2.75" spread="1.32"/>
                    <measurement group_id="O4" value="-3.60" spread="1.25"/>
                    <measurement group_id="O5" value="-5.50" spread="1.47"/>
                    <measurement group_id="O6" value="-6.17" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound</title>
        <description>The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.</description>
        <time_frame>At Day 8, Day 15, Day 22 and end of treatment</time_frame>
        <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle without any active substance applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50 mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound</title>
          <description>The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.</description>
          <population>The 24 participants that were randomized received all products distributed on six different test sites on the body.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 8 (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.22"/>
                    <measurement group_id="O2" value="-0.14" spread="0.32"/>
                    <measurement group_id="O3" value="0.03" spread="0.24"/>
                    <measurement group_id="O4" value="0.00" spread="0.24"/>
                    <measurement group_id="O5" value="-0.30" spread="0.27"/>
                    <measurement group_id="O6" value="-0.39" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.23"/>
                    <measurement group_id="O2" value="-0.45" spread="0.39"/>
                    <measurement group_id="O3" value="-0.16" spread="0.31"/>
                    <measurement group_id="O4" value="-0.25" spread="0.36"/>
                    <measurement group_id="O5" value="-0.51" spread="0.32"/>
                    <measurement group_id="O6" value="-0.68" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.27"/>
                    <measurement group_id="O2" value="-0.54" spread="0.37"/>
                    <measurement group_id="O3" value="-0.15" spread="0.19"/>
                    <measurement group_id="O4" value="-0.24" spread="0.32"/>
                    <measurement group_id="O5" value="-0.57" spread="0.34"/>
                    <measurement group_id="O6" value="-0.68" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 26 (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.30"/>
                    <measurement group_id="O2" value="-0.63" spread="0.39"/>
                    <measurement group_id="O3" value="-0.30" spread="0.31"/>
                    <measurement group_id="O4" value="-0.38" spread="0.30"/>
                    <measurement group_id="O5" value="-0.68" spread="0.34"/>
                    <measurement group_id="O6" value="-0.78" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers by Immunochemistry</title>
        <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
Cells counted per mm^2 were cells that were positive for the indicated biomarker.</description>
        <time_frame>At end of treatment</time_frame>
        <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers by Immunochemistry</title>
          <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
Cells counted per mm^2 were cells that were positive for the indicated biomarker.</description>
          <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Macrophages: CD163</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.9" spread="97.28"/>
                    <measurement group_id="O2" value="197.4" spread="69.51"/>
                    <measurement group_id="O3" value="291.2" spread="100.8"/>
                    <measurement group_id="O4" value="383.5" spread="488.6"/>
                    <measurement group_id="O5" value="178.2" spread="27.96"/>
                    <measurement group_id="O6" value="172.9" spread="40.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dendritic cells CD1a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.8" spread="113.9"/>
                    <measurement group_id="O2" value="42.14" spread="27.81"/>
                    <measurement group_id="O3" value="229.3" spread="134.2"/>
                    <measurement group_id="O4" value="244.0" spread="118.9"/>
                    <measurement group_id="O5" value="34.31" spread="20.00"/>
                    <measurement group_id="O6" value="56.34" spread="33.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-cell biomarker CD3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="593.8" spread="243.9"/>
                    <measurement group_id="O2" value="124.5" spread="105.9"/>
                    <measurement group_id="O3" value="464.2" spread="275.9"/>
                    <measurement group_id="O4" value="492.7" spread="280.4"/>
                    <measurement group_id="O5" value="126.1" spread="95.57"/>
                    <measurement group_id="O6" value="143.9" spread="161.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiogenesis: CD31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.7" spread="165.7"/>
                    <measurement group_id="O2" value="216.3" spread="100.1"/>
                    <measurement group_id="O3" value="331.1" spread="120.9"/>
                    <measurement group_id="O4" value="348.8" spread="158.1"/>
                    <measurement group_id="O5" value="184.2" spread="38.84"/>
                    <measurement group_id="O6" value="186.6" spread="51.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-cell biomarker: CD4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.3" spread="123.9"/>
                    <measurement group_id="O2" value="59.17" spread="41.78"/>
                    <measurement group_id="O3" value="246.4" spread="148.0"/>
                    <measurement group_id="O4" value="239.0" spread="147.3"/>
                    <measurement group_id="O5" value="55.56" spread="44.03"/>
                    <measurement group_id="O6" value="66.95" spread="55.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-cell biomarker: CD45RO</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="752.0" spread="183.1"/>
                    <measurement group_id="O2" value="101.6" spread="78.14"/>
                    <measurement group_id="O3" value="630.1" spread="318.8"/>
                    <measurement group_id="O4" value="643.6" spread="370.4"/>
                    <measurement group_id="O5" value="121.6" spread="50.39"/>
                    <measurement group_id="O6" value="218.2" spread="258.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophages: CD68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370.8" spread="58.56"/>
                    <measurement group_id="O2" value="120.3" spread="61.57"/>
                    <measurement group_id="O3" value="323.1" spread="114.2"/>
                    <measurement group_id="O4" value="303.8" spread="117.8"/>
                    <measurement group_id="O5" value="142.1" spread="58.47"/>
                    <measurement group_id="O6" value="156.8" spread="44.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-cell biomarker: CD8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.5" spread="156.0"/>
                    <measurement group_id="O2" value="60.05" spread="61.95"/>
                    <measurement group_id="O3" value="220.7" spread="123.9"/>
                    <measurement group_id="O4" value="253.2" spread="171.9"/>
                    <measurement group_id="O5" value="66.35" spread="53.30"/>
                    <measurement group_id="O6" value="65.05" spread="72.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers by Immunochemistry: Epidermal Differentiation</title>
        <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.</description>
        <time_frame>At end of treatment</time_frame>
        <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle without any active substance applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers by Immunochemistry: Epidermal Differentiation</title>
          <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.</description>
          <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
          <units>%, positive area/total area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epidermal differentiation: CK10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.14"/>
                    <measurement group_id="O2" value="0.89" spread="0.15"/>
                    <measurement group_id="O3" value="0.77" spread="0.14"/>
                    <measurement group_id="O4" value="0.75" spread="0.11"/>
                    <measurement group_id="O5" value="0.93" spread="0.08"/>
                    <measurement group_id="O6" value="0.89" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epidermal differentiation: CK16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.14"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.08" spread="0.11"/>
                    <measurement group_id="O4" value="0.02" spread="0.04"/>
                    <measurement group_id="O5" value="0.01" spread="0.01"/>
                    <measurement group_id="O6" value="0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers by Immunochemistry: Epidermal Proliferation</title>
        <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm^2 were cells that were positive for the indicated biomarker.</description>
        <time_frame>At end of treatment</time_frame>
        <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle without any active substance applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers by Immunochemistry: Epidermal Proliferation</title>
          <description>3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm^2 were cells that were positive for the indicated biomarker.</description>
          <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554.1" spread="391.9"/>
                    <measurement group_id="O2" value="19.45" spread="28.69"/>
                    <measurement group_id="O3" value="443.3" spread="298.6"/>
                    <measurement group_id="O4" value="354.3" spread="198.2"/>
                    <measurement group_id="O5" value="20.50" spread="29.11"/>
                    <measurement group_id="O6" value="93.49" spread="134.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathology and Histology by Treatment</title>
        <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below:
Morphology of epidermis
Stratum corneum (semi (extent of))
Stratum granulosum (semi (extent of))
Parakeratosis (semi (extent of))
Infiltration of inflammatory cells (semi (extent of))</description>
        <time_frame>At end of treatment</time_frame>
        <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle without any active substance applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathology and Histology by Treatment</title>
          <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below:
Morphology of epidermis
Stratum corneum (semi (extent of))
Stratum granulosum (semi (extent of))
Parakeratosis (semi (extent of))
Infiltration of inflammatory cells (semi (extent of))</description>
          <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infiltration of inflammatory cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.80"/>
                    <measurement group_id="O2" value="0.17" spread="0.41"/>
                    <measurement group_id="O3" value="1.52" spread="0.79"/>
                    <measurement group_id="O4" value="1.53" spread="0.94"/>
                    <measurement group_id="O5" value="0.50" spread="0.55"/>
                    <measurement group_id="O6" value="0.67" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parakeratosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.15"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.39" spread="1.34"/>
                    <measurement group_id="O4" value="1.35" spread="1.11"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                    <measurement group_id="O6" value="0.17" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum Corneum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.83"/>
                    <measurement group_id="O2" value="0.33" spread="0.52"/>
                    <measurement group_id="O3" value="1.52" spread="0.90"/>
                    <measurement group_id="O4" value="1.41" spread="0.94"/>
                    <measurement group_id="O5" value="0.50" spread="0.55"/>
                    <measurement group_id="O6" value="0.33" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum Granulosum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.24"/>
                    <measurement group_id="O2" value="0.17" spread="0.41"/>
                    <measurement group_id="O3" value="1.04" spread="1.26"/>
                    <measurement group_id="O4" value="1.00" spread="1.17"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                    <measurement group_id="O6" value="0.17" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathology and Histology by Treatment: Epidermal Thickness</title>
        <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of Âµm measured on blinded haematoxylin and eosin (HE) sections..</description>
        <time_frame>At end of treatment</time_frame>
        <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle without any active substance applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathology and Histology by Treatment: Epidermal Thickness</title>
          <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of Âµm measured on blinded haematoxylin and eosin (HE) sections..</description>
          <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
          <units>Âµm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.6" spread="58.68"/>
                    <measurement group_id="O2" value="73.81" spread="20.61"/>
                    <measurement group_id="O3" value="187.5" spread="79.65"/>
                    <measurement group_id="O4" value="176.4" spread="49.05"/>
                    <measurement group_id="O5" value="68.48" spread="18.16"/>
                    <measurement group_id="O6" value="66.90" spread="44.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses</title>
        <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study.
In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (MonroeÂ´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.</description>
        <time_frame>At end of treatment</time_frame>
        <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Cream Vehicle</title>
            <description>LEO 29102 cream vehicle without any active substance applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone Dipropionate Cream</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 Cream</title>
            <description>LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 Plus Calcipotriol Cream</title>
            <description>LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 Plus Betamethasone Dipropionate</title>
            <description>LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>DaivobetÂ® Ointment</title>
            <description>DaivobetÂ® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses</title>
          <description>Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study.
In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (MonroeÂ´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.</description>
          <population>Since biopsies were only taken from three out of six sites, not all treatment-block combinations were available.</population>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.26"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.15" spread="0.35"/>
                    <measurement group_id="O4" value="0.17" spread="0.30"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                    <measurement group_id="O6" value="0.05" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to end of Follow-up (Day 43Â±2)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Randomized Participants</title>
          <description>All randomized participants received the six products on six different test sites.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO retains the right to publish the results of this clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

